Passage Bio, Inc. Common Stock (PASG) Stock Price

PASGStock
$4.5234.49%52W
Market Cap$14.54M
P/E
PEG Ratio
Div yield
Beta1.42

PASG Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-63.22%
Price vs S&P 500 (4W)-0.87%
VGM Score32.68

PASG Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$2.83-$2.44+13.93%(+$0.40)
Q4 2025-$2.80-$4.09-46.28%(-$1.29)
Q3 2025-$2.84-$2.44+14.08%(+$0.40)
Q2 2025-$4.15-$2.96+28.67%(+$1.19)

PASG Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.83
3.91
3.89
3.89

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PASGPassage Bio, Inc. Common Stock
D$4.52
AMGNAmgen IncCCB$432.42
GILDGilead Sciences IncCBB$145.68
ARGXargenx SE American Depositary SharesDAB$1023.21
MRNAModerna, Inc. Common StockDCA$137.99
RVMDRevolution Medicines, Inc. Common StockFA$207.88
BIIBBiogen Inc. Common StockCDB$218.50
BNTXBioNTech SE American Depositary ShareCCC$102.08
NBIXNeurocrine Biosciences IncCBC$154.06
EXELExelixis IncCBB$54.45
HALOHalozyme Therapeutics, Inc.CBB$105.35

About Passage Bio, Inc. Common Stock

Passage Bio develops genetic medicines for rare monogenic CNS disorders, including GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The company targets the underlying causes of these neurodegenerative conditions to address significant unmet medical needs.